This article offers a comprehensive review of nanotechnology-based treatments for patients with glaucoma.

Nanotechnology-based drugs will probably be incorporated into the arsenal of glaucoma specialists in the near future, allowing benefits such as reduced side effects, and less frequent dosing, among others.

Toxicity issues related to nanotechnology-based treatments have yet to be addressed to test their safety.

Further human studies in nanomedicine for glaucoma treatment are needed until this promising pharmacological innovation becomes available in the ophthalmologist’s daily therapeutic practice.